Research progress of mesenchymal stem cells/stromal cells and their derivatives against cell senescence in the treatment of osteoarthritis.

Daihua Deng, Yinlan Wu, Tong Wu, Deying Huang, Xiuping Liang, Chunyu Tan, Yanhong Li, Yi Liu

Department of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China. · pubmed

Paper

Abstract

Cellular senescence plays a critical role in the pathogenesis and progression of osteoarthritis (OA), contributing to articular cartilage degradation, chronic inflammation, and joint function impairment. Mesenchymal stem cells/stromal cells (MSCs) and their derivatives have emerged as potential targets for novel therapeutic strategies against cell senescence in OA, as they exert anti-aging effects in repairing damaged cartilage through multiple mechanisms-including regulating age-related signaling pathways, reducing the secretion of pro-inflammatory cytokines, and improving mitochondrial function.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Mesenchymal stem cells and their derivatives can mitigate cell senescence in osteoarthritis through various mechanisms. The paper addresses the potential of MSCs to counteract cellular senescence, which is a fundamental aspect of aging and age-related diseases.

Author of this paper? Send a correction.